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Abstract
To evaluate the safety and efﬁcacy of the surgical use of plasma rich in growth factors ﬁbrin membrane (mPRGF) in different ocular
surface pathologies.
Fifteen patients with different corneal and conjunctival diseases were included in the study. Patients were grouped according to the
use of mPRGF as graft (corneal and/or conjunctival) or dressing; they were also grouped according to the surgical subgroup of
intervention (persistent corneal ulcer [PCU], keratoplasty, superﬁcial keratectomy, corneal perforation, and pterygium). Best
corrected visual acuity, intraocular pressure (IOP), inﬂammation control time (ICT), mPRGF AT (PRGF membrane absorption time),
and the healing time of the epithelial defect (HTED) were evaluated throughout the clinical follow-up time. Safety assessment was also
performed reporting all adverse events.
mPRGF showed a total closure of the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients (13.3%). The mean
follow-up time was 11.1±4.2 (4.8–22.8) months, themean ICT was 2.5±1.1 (1.0–4.0) months, the meanmPRGF ATwas 12.4±2.0
(10.0–16.0) days, and for the global HTED the mean was 2.9±1.2 (1–4.8) months. Results showed an improvement in BCVA in all
patients, with an overall improvement of 2.9 in Vision Lines. The BCVA signiﬁcantly improved (P< .05) in the groups of corneal graft
and dressing. In the PCU subgroup (6 patients), the healing time of epithelial defect was signiﬁcantly reduced (P< .05) in patients
treated only with the mPRGF in comparison to those which mPRGF therapy was associated to the amniotic membrane. The IOP
remained stable (P> .05) throughout the clinical follow-up time. No adverse events were reported after mPRGF use.
The mPRGF is effective and safe as coadjuvant treatment in surgeries related with ocular surface disorders, being an alternative to
the use of amniotic membrane. The mPRGF accelerates tissue regeneration after ocular surface surgery thus minimizing
inﬂammation and ﬁbrosis.
Abbreviations: AM = amniotic membrane, AMT = amniotic membrane transplantation, BCVA = best corrected visual acuity,
DALK = deep anterior lamellar keratoplasty, HTED = healing time of the epithelial defect, ICT = inﬂammation control time, mPRGF =
plasma rich in growth factors ﬁbrin membrane, mPRGF AT = absorption time of mPRGF, NCU = neurotrophic corneal ulcer, PCU =
persistent corneal ulcer, PED = persistent epithelial defect, PK = penetrating keratoplasty, PPK = pseudochamber protected
keratoplasty, PRGF = plasma rich in growth factor, PRP = platelet-rich plasma, TCL = therapeutic contact lenses.
Keywords: corneal and ocular surface diseases, ﬁbrin membrane, plasma rich in growth factors, platelet-rich plasma, PRGF, PRP
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1. Introduction
Ocular surface and corneal diseases are usually caused by
external agents such as alkali burns, physical or mechanical
trauma, or infections. However, they can also be caused by some
chronic scarring keratoconjunctivitis mediated in part by
autoimmune pathology, including cicatricial ocular pemphigoid,
Stevens–Johnson syndrome, atopic keratoconjunctivitis, and
peripheral ulcerative keratitis. These pathologies can be
complicated by corneal ulcers and perforations that may
compromise the integrity of the eyeball and visual viability.[1]
In order to heal some corneal defects and reduce the risk of ocular
perforation, amniotic membrane transplantation (AMT), tissue
adhesives (collagen or ﬁbrin), and tissue patches derived from
animals have historically been used, although they are sometimes
insufﬁcient.[2] The amniotic membrane (AM) has been used since
the early twentieth century. In fact, it was used for the ﬁrst time in
the ophthalmology ﬁeld in the 1940s in patients who suffered
alkali burns to the eyes. The AM stimulates the ocular surface
wound healing with minimal inﬂammation and scarring by
combining mechanical protection and biological factors. The
main indications for the use of AM include corneal diseases
and trauma, and it also includes disorders that involve the
conjunctiva, sclera, and eyelids.[3] The AM has been widely used
in the management of persistent epithelial defects (PEDs),
neurotrophic ulcers, corneal damage caused by chemical agents,
pterygium, and corneal surface reconstruction.[4,5] However,
there are some limitations in the use of AM, because it is a
biological product with great variability in its quality and
biological capacity; there is a high potential risk for biological
contamination; and its availability is scarce and its cost is
high.[6,7]
Plasma rich in growth factors (PRGF) is a standardized and
optimized technology for tissue repair and regeneration. It is
based on the preparation of several autologous formulations
obtained from the patient’s own blood, including growth factors-
rich eye drops, a 3D ﬁbrin scaffold, and a biomimetic and elastic
membrane (PRGFs ﬁbrin membrane [mPRGF]).[8–10] The
properties of these formulations are similar to those of AM,
such as its capability to induce tissue regeneration, its bactericidal
and bacteriostatic activity, its anti-inﬂammatory, and its
antiﬁbrotic potential.[11–14] Furthermore, these characteristics
have been widely evidenced in multiple preclinical and clinical
studies in the ophthalmology ﬁeld.[8,10,15,16] Particularly, the
potential beneﬁts of mPRGF have been evaluated in several
studies using it alone or in combination with other membranes
like AMor bovine pericardium collagenmembrane; in all of these
studies, a stable closure of corneal ulcers was observed after
treatment with mPRGF with no evidence of infection, inﬂamma-
tion, or pain.[17–19]
The mPRGF is able to retain for more than a week almost 30%
of the growth factors content involved in tissue regeneration
including platelet-derived growth factor-AB, vascular endothelial
growth factor, hepatocyte growth factor, and insulin-like growth
factor-1, among others.[13] Leukocytes are not collected during
mPRGF preparation thus reducing the content in pro-inﬂamma-
tory proteins (IL-1b, IL-16, among others), characteristic that
differentiates the mPRGF from other platelet-rich plasmas (PRPs)
membranes.[12] One of the main components of the mPRGF is the
ﬁbrin scaffold, in which a 3D ﬁbrin network enriched in growth
factors and proteins, interacts with the patient’s own extracellu-
lar matrix, and cellular components thus promoting tissue
regeneration and wound healing.[11]
The present work aims to provide preliminary information
about the safety and efﬁcacy of the surgical use of mPRGF in
different ocular pathologies (corneal and conjunctival) as a graft
for corneal and/or conjunctival pathologies or even as a dressing.
To the best of our knowledge, this is the ﬁrst clinical study of
translational research that addresses the surgical regeneration of
the ocular surface by using autologous mPRGF.
2. Materials and methods
2.1. Patients
A descriptive and retrospective clinical study was carried out to
analyze the results obtained from patients subjected to an ocular
surface and cornea surgical pathology using the mPRGF as a
single therapy or associated with another surgical technique to
achieve an anatomical and functional recovery. The study was
conducted at the University Institute Fernandez-Vega (Oviedo,
Spain) between June 2015 andMay 2017. Informed consent was
obtained from all participants included in the study. All the
principles of the Declaration of Helsinki were fulﬁlled to carry
out this study. The Institutional Clinical Research Committee
approved this study.
The patients included in this study suffered from corneal and/
or conjunctival pathologies, and were susceptible to surgical
treatment. A total of 15 patients with different surgical
pathologies were included: PED, neurotrophic corneal ulcer
(NCU), traumatic corneal perforation, failed keratoplasty, band
keratopathy, and pterygium with important inﬂammatory
component. These patients did not respond to medical therapies
including corticosteroids, nonsteroidal anti-inﬂammatory drugs,
artiﬁcial tears, therapeutic contact lenses (TCL), some of them
having also failed to AMT therapy and corneal surgeries such as
keratoplasty.
The patients were divided in different surgical subgroups:
persistent corneal ulcer (PCU, including those types that did not
respond to treatment), corneal perforation, keratoplasty, super-
ﬁcial keratectomy, and pterygium removal. The use of mPRGF
was grouped according to the surgical application as corneal
pathology graft, conjunctival pathology graft, corneal and
conjunctival pathology graft, or dressing. Patient’s baseline data
of gender, age, presurgical diagnosis, time of disease evolution,
previous ophthalmic surgeries, and associated ﬁndings were
obtained from the medical records.
2.2. Preparation of the mPRGF
To obtain PRGF membranes (mPRGF) for ophthalmic applica-
tion, 81 mL of blood were collected in 9 mL tubes with 3.8%
sodium citrate as anticoagulant. The blood samples were
centrifuged at 580g at room temperature for 8 min in an
Endoret System centrifuge (BTI Biotechnology Institute, S.L.,
Miñano, Álava, Spain). The plasma column was collected into
fraction 2 (F2) deﬁned as the 2mL PRP just above the leukocyte
buffy coat, and fraction 1 (F1) deﬁned as the remaining plasma
volume above the F2. For each membrane, 5 mL of F2 were
activatedwith 10% calcium chloride and incubated in wells of 35
mm diameter at 37°C for 30 min. Once ﬁbrin clots were formed,
they were placed in a shaper and pressed for 30s, obtaining
mPRGF of 500mmof thickness. Then, the mPRGF obtained were
mounted on nitrocellulose discs to make their handling easier
(Fig. 1).[20] The PRGF eye drops were also manufactured,
according to the protocol described by Anitua et al.[15] After the
Sanchez-Avila et al. Medicine (2018) 97:17 Medicine
2
surgery, the PRGF eye drops were applied topically (in the
conjunctival sac) 4 times per day for 6 weeks in the affected eye.
2.3. Surgical technique
A retrobulbar anesthesia (mepivacaine hydrochloride, 2%; B.
Braun Melsungen AG; Arnhem, Netherlands) was performed in
all patients using amaximumof 4mL of anesthetic. The eyes were
rinsed with 20% povidone iodine 15 min after the anesthetic
administration. The eyelids were opened with Castroviejo
blepharostat. When mPRGF was used as a corneal pathology
graft, the injured epithelium was removed mechanically with a
surgical knife. Then, mPRGF was placed on the corneal surface,
extended and trimmed down to adapt it to the corneal surface.
Continuous suture for 360° was carried out with 10-0 nylon to
stitch the mPRGF to the sclerocorneal bed, and ﬁnally, TCL was
placed above the membrane (Fig. 2). WhenmPRGFwas used as a
conjunctival pathology graft (pterygium surgery), it was ﬁrst
dissected and cut, the recipient bed was rinse, and then the
mPRGFwas placed on the surgical bed and trimmed down, nylon
10-0 separated stitches were sutured, and ﬁnally, a TCL were
placed over the membrane.WhenmPRGFwas used as a dressing,
Figure 1. Preparation process of plasma rich in growth factors membranes (mPRGF). (A) Blood tube after centrifugation. (B) Coagulation of ﬁbrin clot. (C) mPRGF
on the former. (D) mPRGF obtained after conformation. (E) Membrane mounted on nitrocellulose disk.
Figure 2. Use of the mPRGF in persistent epithelial defects. (A) Intraoperative image of PED. (B) Epithelium debridement. (C) Placement of mPRGF on corneal
surface. (D) Extending and trimming down of mPRGF. (E) Running suture of mPRGF to cornea with 10/0 nylon. (F) Therapeutic contact lens placement over mPRGF
after surgery. mPRGF = plasma rich in growth factors membranes, PED = persistent epithelial defect.
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the initial procedure was performed (e.g., cataract surgery by
phacoemulsiﬁcation), followed by corneal transplant surgery
such as deep anterior lamellar keratoplasty (DALK), penetrating
keratoplasty (PK), or pseudochamber protected keratoplasty
(PPK). Subsequently, a 5-mm scleral dissection plane toward the
posterior segment was carried out after 360° conjunctival
peritomy, then mPRGF was placed, trimmed, and ﬁtted below
the dissected conjunctiva, after that a continuous suture with
Vycril 8-0 between mPRGF and adjacent conjunctiva was
performed. Finally, a TCL was placed on the ocular surface
(Fig. 3). Along the postoperative period patients were treated
with anti-inﬂammatory drugs, antibiotic, and TCL. Oral steroids
therapy was continued in those patients who were taking chronic
treatment.
2.4. Postsurgery follow up
All patients were followed daily for 7 days, then once a week for 4
weeks, and ﬁnally, each month until clinical resolution. Several
outcome variables were collected to measure the efﬁcacy of
mPRGF treatment including type of surgery, concomitant
surgical treatment, best corrected visual acuity (BCVA in
LogMAR), intraocular pressure (IOP, in mm Hg, measured
with Icare PRO tonometer, 2015, Finland), inﬂammation control
time (ICT, time at which the relief of the eye is established, no
redness, no pain, no ocular surface symptoms), and mPRGF AT
(absorption time, time at which the PRGF membrane was
completely reabsorbed). Healing was also evaluated under slip-
lamp scoring it from 1 to 3; 1—complete healing (ulcer closure), 2
—partial healing (small PED < 1mm), and 3—no healing (large
and persistent PED, no ulcer closure); the healing time of the
epithelial defect (HTED) was also evaluated, deﬁned as the time
in which more than 80% of the epithelial defect has been healed.
The clinical follow-up time was recorded for each patient
included in the study, as well as the lines of vision gained by each
surgery group. The safety of treatment with mPRGF was also
evaluated, recording and treating any adverse event or
complication that appeared after the application of mPRGF.
2.5. Statistical analysis
A descriptive statistic was made using absolute and relative
frequency distributions for qualitative variables, and analysis of
mean values and standard deviations for quantitative variables.
Different normality tests (Kolmogorov–Smirnov and Shapiro–
Wilk) were performed on each variable sample. Any potential
difference observed between baseline and after mPRGF treatment
was analyzed using the statistical paired t test. The Mann–
Whitney U test was used to analyze independent samples. The
analysis of variance test was performed for the comparison
between groups and the Jonckheere–Terpstra test was also used
to evaluate nonparametric variables. The level of statistical
signiﬁcance was set at P< .05. The statistical software package
SPSS v19.0 forWindows (SPSS Inc., Chicago, IL) was used for all
statistical analyses.
3. Results
Fifteen patients with corneal and ocular surface pathologies were
treated with mPRGF. The mean age of patients was 62.7±17.3
years (ranged from 27 to 82). Three women (20%) and 12 men
(80%) were included in the study (Tables 1 and 2). Four cases
received oral corticosteroids chronically and their treatment was
maintained throughout the follow-up, no ophthalmological
complications were observed in these patients. Previously to
the mPRGF treatment, 3 patients had received AMT on several
times (patients 2, 12, and 13) with poor response to the
treatment; 11 (73.3%) patients received therapy with TCL
without improvement in the healing of their corneal pathology;
and 6 cases (40.0%) had some type of corneal transplantation.
The frequency of cases according to the surgical subgroup was
as follows: PCU included 6 patients (40.0%), keratoplasty
Figure 3. mPRGF treatment after cataract surgery followed by deep anterior lamellar keratoplasty. (A) Leukoma secondary to herpes simplex virus and bacterial
corneal abscess. (B) Corneal dissection until predescemet space. (C) Corneal donor button suture with 10/0 nylon and 360° conjunctival peritomy. (D) Application of
conformed mPRGF to the ocular surface. (E) Placement of mPRGF inside the subconjunctival space. (F) Running suture of the mPRGF to the conjunctiva with vicryl
8/0. mPRGF = plasma rich in growth factors ﬁbrin membrane.
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included 4 patients (26.7%), 3 patients underwent superﬁcial
keratectomy (20.0%), 1 patient underwent corneal perforation
(6.7%), and pterygium removal included 1 patient (6.7%).
According to the surgical application, mPRGF was used as
corneal pathology graft in 7 cases (46.7%), conjunctival
pathology graft in 1 case (6, 7%), graft of corneal and
conjunctival pathology in 3 cases (20.0%), and dressing in 4
cases (26.7%). The AM was used in 5 patients (33.3%) as a
dressing over the mPRGF (3—PCU, 2—superﬁcial keratectomy),
and in 4 patients some type of keratoplasty was performed (1
patient underwent PPK, 2 patients underwent PK, DALK +
cataract surgery was carried out in 1 patient) was used associated
with mPRGF as a dressing. The latter patients received oral
prednisone (1mg/kg, in descending dose for 1 month) within the
institution’s keratoplasty protocol. All patients were also treated
after the surgery with TCL for 1 month (Tables 3 and 4).
The BCVA improved in all patients treated with mPRGF with
an overall improvement of 2.9 in Vision Lines. Vision lines
improved signiﬁcantly (P< .05) in 3.1 and 3.3 for the corneal
graft group and the dressing group, respectively. The improve-
ment was 2.7 for the corneal/conjunctival graft and 1.0 for
conjunctival graft (Fig. 4). The baseline overall values of BCVA
(LogMAR) were 2.02±0.87 (ranged from 0.22 to 3.00) and after
surgical treatment the BCVA was 0.74±0.63 (ranged from 0.00
to 2.00) (P= .001), achieving an improvement of the overall
visual acuity of 65.4%. An improvement of 47.1% (P= .021) in
visual acuity was achieved in the PCU subgroup; however, no
statistically signiﬁcant differences were foundwhen BCVA results
were compared between subgroups with and without AMT. On
the other hand, visual acuity improvement was achieved in the
92% of patients with corneal perforations (Table 5). In the total
group, the IOP remained stable throughout the clinical follow-up,
with an initial IOP of 12.9±4.2 (3.0–19.0) and a ﬁnal IOP of
12.9±2.2 (10.0–17.0) mm Hg (P= .96). The mean follow-up
time was 11.1±4.2 (4.8–22.8) months, the mean ICT was 2.5±
1.1 (1.0–4.0) months, the mean mPRGF AT was 12.4±2.0
(10.0–16.0) days, and for the global HTED the mean value was
2.9±1.2 (1–4.8) months. At the ﬁnal follow-up time, complete
healing was observed in 13 patients (86.7%) and partial healing
was showed in 2 patients (13.3%). The differences in the time
variables for comparisons between surgical subgroups were not
statistically signiﬁcant (P> .05).
When outcome variables were evaluated in the PCU surgical
subgroup attending to whether they were treated alone with
mPRGF (3 cases) or associated with the AMT (3 cases), the
following results were obtained (Fig. 5): The percentage increase
in BCVA for the subgroup treated alone with mPRGF was
77.6%, and for the mPRGF group associated with AMT was
32.6% (P= .827). HTED variable (months) showed values of 2.4
and 4.0 for the subgroup treated alone with mPRGF and
associated with AM, respectively, being these differences
statistically signiﬁcant (P= .046). No statistical signiﬁcances
were observed between both subgroups (treated alone with
mPRGF or associated with AM) for the rest of the outcome
Table 1
Baseline data of patients.
Patient Gender Age Presurgical diagnosis TDE, mo Associated ﬁndings Previous surgeries
1 M 63 PED/LSCD, Symb. 5 Distichiasis —
2 M 48 NCU 27 High myopia, DTS, KC, HSVK DALK, AMT (x2), PPK
3 M 82 NCU 4 DTS PCS
4 M 38 TCP 0.1 Metallic CFC Cyan
5 M 27 PED/LSCD 3 HSVK DALK
6 F 75 NCU 2 Ocular rosacea, HSVK —
7 F 80 NCU 7 ED ECS
8
∗
M 82 Failed PPK/PED 18 Aphakia PPK
9 M 77 BK 8 ED, PDR, Glau PCS, DALK
10 F 78 PED post-PCS 2 LSCD PCS
11 M 49 BK 5 Amblyopia, DTS PTK, DALK
12
∗
M 59 BK 4 Glau PCS, DALK (x2), AMT (x3)
13
∗
M 72 NCU/LSCD 14 HSVK, ED AMT(x2)
14
∗
M 54 PED/failed PK 16 LSCD PK
15 M 56 Pterygium 12 Conjunctival inﬂammation —
AMT= amniotic membrane transplantation, BK=band keratopathy, CFC= corneal foreign body, Cyan= cyanoacrylate (tissue adhesive), DALK=deep anterior lamellar keratoplasty, DTS=dysfunctional tear
syndrome (dry eye syndrome), ECS= extracapsular cataract surgery, ED= endothelial dystrophy, Glau=glaucoma, HSVK=herpes simplex virus keratitis, KC= keratoconus, LSCD= limbal stem cell deﬁciency,
NCU=neurotrophic corneal ulcer, PCS=phacoemulsiﬁcation cataract surgery, PDR=proliferative diabetic retinopathy, PED=persistent epithelial defect, PK=penetrating keratoplasty, PPK=pseudochamber
protected keratoplasty, PTK=phototherapeutic keratectomy, Symb= symblepharon, TCP= traumatic corneal perforation, TDE= time of disease evolution.
∗
Use of oral corticosteroids chronically.
Table 2
Baseline characteristics of patients grouped by ﬁndings.
Patients, n (%) 15 (100)
Eyes, n (%) 15 (100)
Age, mean ± SD (range), y 62.7±17.3 (27–82)
Gender, M/F, n (%) 12 (80)/3 (20)
Presurgical diagnosis, n (%) 15 (100)
NCU, n (%) 5(33.3)
BK, n (%) 3 (20.0)
PED, n (%) 3 (20.0)
FK, n (%) 2 (13.3)
TCP, n (%) 1 (6.7)
Ptg, n (%) 1 (6.7)
Previous AMT, n (%) 3 (20.0)
AMT x2, n (%) 2 (13.3)
AMT x3, n (%) 1 (6.7)
Previous Kt, n (%) 6 (40.0)
TDE, mean ± SD (range), mo 8.5±7.5 (0.1–27)
AMT= amniotic membrane transplantation, BK=band keratopathy, F= female, FK= failed
keratoplasty, Kt=keratoplasty, M=male, NCU=neurotrophic corneal ulcer, PED=persistent
epithelial defect, Ptg=pterygium, SD= standard deviation, TCP= traumatic corneal perforation,
TDE= time of disease evolution.
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variables measured, being, respectively, of 2.0 and 3.3 for the ICT
(months) (P= .114); 7.7 and 13.3 months (P= .127) for the
follow-up time (months); and ﬁnally, 12.67 and 11.67 days
(P= .658) for the mPRGF AT. The variables for the surgical
subgroup of superﬁcial keratectomy did not show statistically
signiﬁcant differences among the groups (P> .05) depending on
whether they had used AMT or not.
Patient number 4 is represented in Fig. 6 showing an ocular
trauma due to a central corneal metallic foreign body, which
caused maceration and stromal lysis with corneal perforation,
and who was urgently surgically treated with mPRGF (a central
plug and corneal dressing with a second layer of mPRGF). The
latter allowed the corneal stabilization. Then, a corneal
transplant (DALK) was performed in a second surgical time.
This last patient has a ﬁnal visual recovery of 7 lines of vision and
was stable for 22.8 months of the follow-up period.
No adverse events were reported neither with the use of
mPRGF nor with the associated treatments. Patients showed no
pain, no discomfort, or any other symptoms during the
postoperative follow-up period. No infection or inﬂammation
symptoms were manifested in clinical follow-up time. Only 1
patient required temporary tarsorrhaphy, which was opened 8
days after surgery without any incidents.
4. Discussion
The AM has been widely used in surgical pathologies
of the ocular surface and cornea, because it promotes
epithelialization and exhibits antiﬁbrotic, anti-inﬂammatory,
anti-angiogenic, and anti-microbial properties.[21] However,
the AM has some disadvantages such as the need for a
tissue bank for its production, the risk of viral infections
transmission by the donor, variability in production protocols,
and the need for storage.[22] Classically the AM has been used
surgically, as a temporary patch or as a permanent graft,
however, due to its cellular proliferation properties, it has also
Table 3
Patient outcomes treated with mPRGF.
Patient mPRGF application Surgery iBCVA (LogMAR) fBCVA (LogMAR) iIOP fIOP Follow up, mo ICT, mo HTED, mo mPRGF AT, d Healing
∗
1 Corneal/conjunctival mPRGF/AMT/Tar 2.000 2.000 12 12 11.6 4 4.5 12 2
2 Corneal mPRGF/AMT 3.000 2.000 19 15 14.2 4 4.8 10 1
3 Corneal mPRGF 2.000 0.523 12 10 11.8 2 2.5 15 1
4 Corneal/conjunctival mPRGF 2.000 0.155 3 10 22.8 1 1.3 11 1
5 Corneal mPRGF/AMT 2.000 0.699 16 17 13.3 2 2.8 13 1
6 Corneal mPRGF 1.000 0.222 15 10 6.3 2 2.5 12 2
7 Dressing PPK/mPRGF 2.000 0.699 13 14 11.2 1 1.3 12 1
8 Dressing PK/mPRGF 3.000 1.000 18 12 8.2 2 2.2 15 1
9 Corneal/conjunctival mPRGF 3.000 1.000 16 16 12.3 2 2.2 10 1
10 Corneal mPRGF 0.222 0.000 10 13 4.8 2 2.2 11 1
11 Corneal mPRGF/AMT 1.000 0.398 12 12 7.2 3 3.5 10 1
12 Corneal mPRGF/AMT 2.000 0.398 14 15 12.1 4 4.5 12 1
13 Dressing DALK/PCS/mPRGF 2.000 0.155 6 14 9.2 3 3.5 16 1
14 Dressing PK/mPRGF 3.000 0.523 12 12 12.1 4 4.2 12 1
15 Conjunctival PtE/mPRGF 0.046 0.000 15 12 9.2 1 1.0 15 1
AMT= amniotic membrane transplantation, DALK=deep anterior lamellar keratoplasty, fBCVA= ﬁnal best corrected visual acuity, fIOP= ﬁnal intraocular pressure (mm Hg), HTED=healing time of the epithelial
defect (months), iBCVA= initial best corrected visual acuity, ICT= inﬂammation control time (months), iIOP= initial intraocular pressure (mm Hg), mPRGF AT=mPRGF absorption time, mPRGF=PRGF
membrane, PCS=phacoemulsiﬁcation cataract surgery, PK=penetrating keratoplasty, PPK=pseudochamber protected keratoplasty, PtE=pterygium excision, Tar= tarsorrhaphy.
∗
1—complete healing (ulcer closure), 2—partial healing (small persistent epithelial defect (PED) <1 mm), 3—no healing (large and persistent PED, no ulcer closure).
Table 4
Application of mPRGF according to surgical subgroup.
Surgical subgroups
mPRGF application
n (%)Corneal Conjunctival Corneal/conjunctival Dressing
Persistent corneal ulcer, n (%) — — — — 6 (40.0)
Without AMT, n (%) 3 (20.0) — — — 3 (20.0)
With AMT, n (%) 2 (13.3) — 1 (6.7) — 3 (20.0)
Keratoplasty, n (%) 4 (26.7)
PK, n (%) — — — 2 (13.3) 2 (13.3)
PPK, n (%) — — — 1 (6.7) 1 (6.7)
DALK + PCS, n (%) — — — 1 (6.7) 1 (6.7)
Superﬁcial keratectomy, n (%) — — — — 3 (20.0)
Without AMT, n (%) — — 1 (6.7) — 1 (6.7)
With AMT, n (%) 2 (13.3) — — — 2 (13.3)
Corneal perforation, n (%) — — 1 (6.7) — 1 (6.7)
Pterygium removal, n (%) — 1 (6.7) — — 1 (6.7)
Total 7 (46.7) 1 (6.7) 3 (20.0) 4 (26.7) 15 (100)
AMT= amniotic membrane transplantation, DALK=deep anterior lamellar keratoplasty, mPRGF=PRGF membrane, PCS=phacoemulsiﬁcation cataract surgery, PK=penetrating keratoplasty, PPK=
pseudochamber protected keratoplasty.
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been recently used as scaffolding for epithelial limbal stem cell
cultures.[23]
The ex vivo cultured limbal epithelial transplantation with AM
as surgical therapy for the treatment of limbal stem cell deﬁciency
has been shown to be effective in recovering the ocular surface
and improving visual acuity.[24] It has been observed in in vitro
studies that the AM can maintain the limbal epithelial stem cells
quiescent, which supports the utility of the AM in the ex vivo
cultured limbal epithelial transplantation.[25] In another in vitro
study, it was demonstrated the superior ability of carbodiimide
cross-linked denuded amniotic membrane against the denuded
AM to preserve limbo-corneal epithelial progenitor cells, ﬁnding
that could be crucial for future basic investigations using the AM
as scaffold.[26]
Platelets play an important role in homeostasis, preventing
blood loss at sites of vascular injury. At the same time they
constitute a natural reservoir of growth factors, adhesive
proteins, and cytokines within their alpha granules.[27] These
proteins and other molecules stored in the alpha-granules are
involved in tissue repair and healing processes. Autologous PRP
preparations have been used since 1999 to accelerate tissue
regeneration process in different medical ﬁelds such as
maxillofacial surgery, tendon repair, joint surgery, ulcer
treatment, and dental surgery.[28–31]
Figure 4. BVCA (LogMAR) outcomesmeasured before and after mPRGF treatment in the different groups included in the study.
∗
Statistically signiﬁcant differences
(P< .05) before versus after treatment with mPRGF. BCVA = best corrected visual acuity, mPRGF = plasma rich in growth factors ﬁbrin membrane.
Table 5
Visual acuity outcomes measured before and after mPRGF therapy.
iBCVA fBCVA P
Total group, mean ± SD (range) 2.02±0.87 (0.22–3.00) 0.74±0.63 (0.00–2.00) .001
PCU, mean ± SD (range) 1.70±0.96 (0.22–3.00) 0.90±0.88 (0.00–2.00) .021
Without AMT, mean ± SD (range) 1.07±0.89 (0.22–2.00) 0.24±0.26 (0.00–0.52) .111
With AMT, mean ± SD (range) 2.33±0.58 (2.00–3.00) 1.57±0.75 (0.70–2.00) .182
Keratoplasty, mean ± SD (range) 2.50±0.56 (2.00–3.00) 0.59±0.35 (0.16–1.00) .004
Superﬁcial keratectomy, mean ± SD (range) 2.00±1.00 (1.00–3.00) 0.60±0.34 (0.40–1.00) .111
AMT= amniotic membrane transplantation, fBCVA= ﬁnal best corrected visual acuity, iBCVA= initial best corrected visual acuity, mPRGF=PRGF membrane, PCU=persistent corneal ulcer, SD= standard
deviation.
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PRPs include a large list of techniques and therapies generally
distinguished by concentrating platelets and sometimes leuko-
cytes within a plasma liquid volume. Most of these approaches
allow the formation of ﬁbrin scaffolds for the differentiation of
several cell types thanks to the physical and mechanical
properties.[32] However, the wide range of PRP protocols
reported so far show signiﬁcantly different clinical results leading
to general confusion. Anitua et al demonstrated that leukocyte-
free ﬁbrin scaffolds obtained with PRGF (PRGF-Endoret)
technology were more stable than those containing leukocytes.
Furthermore, leukocytes inclusion modiﬁes the content in
growth factors increasing the concentration of proinﬂammatory
cytokines.[12]
Optimal alternatives to cell carrier materials for ocular surface
reconstruction should be optically transparent, biocompatible
and should have enough biomechanical strength to be able to
suture it to the ocular surface tissues and it should be reproducible
in their production at low cost.[2]
Interestingly, other authors have found similar results to the ones
presented herein. For example, Alio et al described the use of
autologous ﬁbrin membrane as a safe and effective alternative for
the treatmentof corneal ulcershealing.[19] Theautologousoriginof
ﬁbrin membrane is a clear advantage with respect to other
biomaterials such as AM or bovine pericardium, especially the
mPRGF due to the possibility of preparing into the hospital and
even in the same operating room, unlike the previous ones that
depends on the availability of the tissue centers.[33] The effect of
platelet-rich ﬁbrin (PRF) membrane has been investigated in an
animal model with conjunctival lesion. This study demonstrated
the beneﬁcial effect for the conjunctival healing, due to its chemical
and support effects for cell growth and proliferation; the
autologous PRF membrane is a growth factors-enriched endoge-
nous scaffold very useful for ocular surface reconstruction.[34]
AM applications have been previously described for the
treatment of PEDs, neurotrophic ulcers, chemical damage,
pterygium, and conjunctival surface reconstruction with clear
Figure 5. Outcome variables in surgical subgroup PCU according to association with AMT. AMT = amniotic membrane transplantation, BCVA = best corrected
visual acuity, HTED = healing time of the epithelial defect, ICT = inﬂammation control time, mPRGF = plasma rich in growth factors ﬁbrin membrane, mPRGF AT =
absorption time of mPRGF, PCU = persistent corneal ulcer. ∗P< .05.
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beneﬁts.[4] However, this treatment shows some drawbacks such
as the risk to suffer a biological contamination, the high
variability of clinical results due to the nonstandardized
production protocols, the low availability of this product, and
because it is an expensive treatment.
mPRGF has been used in several medical ﬁelds including
dermatology, dentistry, traumatology, and orthopedics for the
treatment of different medical situations such as chronic
cutaneous ulcers, Achilles tendon surgery, and oral implantol-
ogy.[29,35,36] To our knowledge, this is the ﬁrst translational
research study that successfully uses mPRGF for treating corneal
and ocular surface pathologies in a cohort of patients with
different indications such as PED, band keratopathy, NCU,
corneal perforation, failed keratoplasty, and pterygium.
Several studies have demonstrated that PRGF technology has
similar biological features as AM, for instance regenerative, anti-
inﬂammatory, antiﬁbrotic, and anti-microbial properties.[37–39]
However, it is important to highlight some advantages of mPRGF
when compared with AM and other biomaterials. Some of these
include the standardized protocol of PRGF, which will ensure the
reproducibility of the treatment, the less economic impact related
to its preparation and use, the fast clinical availability, and the
advantage in terms of its autologous origin, avoiding the risk of
viral or prions transmission. Furthermore, it is also important to
highlight that PRGF eye drops are obtained in the same process of
mPRGF preparation. PRGF eye drops can be used in the
postsurgical treatment, thus accelerating the ocular surface tissue
regeneration.
The present study presents some limitations that should be
considered. One important issue is that the study has a
retrospective design. Furthermore, the number of patients
included in the study is low and their initial diagnosis is variable.
However, this study has an adequate follow-up time with good
functional and structural results. Future randomized clinical
studies with a higher number of patients will be necessary to
properly conﬁrm these initial results.
Our preliminary results suggest that mPRGF which is easy to
prepare from the patient’s own blood and it would be available
for its use in the operating room in 40 to 60 min, could be an
alternative if AM would not be available. Results show a
complete healing in the 87% of patients included in the study and
a signiﬁcant improvement of BCVA in all patients treated with
mPRGF with no adverse effects reported. Furthermore, it is
important to highlight that mPRGF and PRGF eye drops could be
obtained in the same process, using the latter as postsurgical
treatment for the ocular surface regeneration in the postoperative
period. In addition, mPRGF can be applied in those pathologies
in which corneal and conjunctival epithelium are compromised
and in several types of corneal transplants as regenerative
treatment thus minimizing inﬂammation and ﬁbrosis processes.
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